2상모집 예정

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

연구 개요

The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with platinum-doublet chemotherapy. All participants will be given with albumin-bound paclitaxel, lenvatinib and pembrolizumab.

스폰서: 협력: 머크(MSD)
적응증: Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
중재: pembrolizumab, lenvatinib, albumin-bound paclitaxel
목표 등록: 28명
시작일: 2023-10-01
완료(예정): 2026-10-01
등록번호: NCT06028633 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.